clinical trial · NCT06038058
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.·phase1·recruiting·n = 164
Advanced MalignanciesBRY812 for injection
brief summary
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BRY812 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BRY812 for injection in patients with advanced malignancies. Patients will receive treatment every 3 weeks until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.
started
Oct 10, 2023
primary completion
Aug 1, 2028
completion
Dec 1, 2028
last updated
Dec 30, 2025
official title
A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BRY812 for Injection in Patients With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol